Presented at ASCO: the first RCT of CAR T-cell therapy in solid tumours
About this episode
Changsong Qi discusses a phase 2 trial of CAR T-cell therapy for advanced gastric cancer with hosts Chloe Wilson and Ben Abbott.
Changsong Qi joins Chloe Wilson and Ben Abbott of The Lancet to discuss their recently published phase 2 randomised controlled trial investigating Claudin-18 isoform 2-specific CAR T-cell therapy for previously treated advanced gastric or gastro-oesophageal junction cancer. Read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00860-8/fulltext?dgcid=buzzsprout_icw_podcast_May_25_lancet Continue this conversation on social! Follow us today at... https://thel...
People in this episode
Hosts: Chloe Wilson, Ben Abbott
Guest: Changsong Qi
Topics covered
- CAR T-cell therapy
- solid tumours
- randomised controlled trial
- gastric cancer
- oncology
Keywords
- CAR T-cell therapy
- solid tumours
- gastric cancer
- randomised controlled trial
- ASCO
Mentioned in this episode
Organizations: The Lancet
Books & works: Claudin-18 isoform 2-specific CAR T-cell therapy
Places: advanced gastric or gastro-oesophageal junction cancer
More episodes of The Lancet in conversation with
- Louise Chappell and Na’ama Carlin on Personal Cancer Stories
- Susannah Stanway on the London Global Cancer Week
- Carlos Monteiro, Camila Corvalán, and Phil Baker on Ultra-Processed Foods and Human Health
- Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma
- Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC
- Presented at ESMO: the POTOMAC study on immunotherapy in non-muscle-invasive bladder cancer
Explore listener stats, chart rankings, contacts and more on the The Lancet in conversation with podcast page.